Analysts Are Bullish on These Healthcare Stocks: Ultragenyx Pharmaceutical (RARE), Vir Biotechnology (VIR)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ultragenyx Pharmaceutical (RARE – Research Report) and Vir Biotechnology (VIR – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ultragenyx Pharmaceutical (RARE)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Ultragenyx Pharmaceutical, with a price target of $50.00. The company’s shares closed last Monday at $22.51.
According to TipRanks.com, Selvaraju is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ultragenyx Pharmaceutical with a $53.35 average price target, a 133.1% upside from current levels. In a report issued on February 12, RBC Capital also maintained a Buy rating on the stock with a $35.00 price target.
See today’s best-performing stocks on TipRanks >>
Vir Biotechnology (VIR)
In a report released today, Alec Stranahan from Bank of America Securities reiterated a Buy rating on Vir Biotechnology, with a price target of $17.00. The company’s shares closed last Monday at $7.43, close to its 52-week low of $6.40.
According to TipRanks.com, Stranahan is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Vir Biotechnology with a $19.17 average price target, implying a 154.2% upside from current levels. In a report issued on February 9, Needham also maintained a Buy rating on the stock with a $14.00 price target.
